Compare FSFG & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | RPID |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 178.6M |
| IPO Year | 2008 | 2021 |
| Metric | FSFG | RPID |
|---|---|---|
| Price | $32.39 | $3.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $8.00 |
| AVG Volume (30 Days) | 18.4K | ★ 150.7K |
| Earning Date | 01-27-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | ★ 23.59 | 16.63 |
| 52 Week Low | $21.63 | $0.98 |
| 52 Week High | $33.35 | $4.50 |
| Indicator | FSFG | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 51.09 |
| Support Level | $31.28 | $2.70 |
| Resistance Level | $32.77 | $3.69 |
| Average True Range (ATR) | 0.46 | 0.23 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 56.52 | 69.70 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.